A Real World Case Study : Presented by Dr Kenny Douglas

Author: Dr Kenny Douglas

Consultant Haematologist, Beatson West of Scotland Cancer Centre, Glasgow

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Prescribing Information for SARCLISA^®▼ (isatuximab) can be found via the Product Card at the bottom of the page.

In this video, you'll learn about

A case study presented by Dr Douglas of a 44 year old RRMM patient with high risk cytogenetics who previously underwent two ASCTs, had a short reponse to treatment at 3^rd line and subsequently received SARCLISA^® + Pd at 4^th Line.

Overview of SARCLISA®

Find out more about SARCLISA^® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA^®patient information.

1/3

Overview of SARCLISA®

Find out more about SARCLISA^® + Pd efficacy and safety data and dosing information.

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information

Patient Booklet

Download SARCLISA^®patient information.

Get in touch with the Oncology Team

Relapsed Refractory Multiple Myeloma Product

Learn more →

Prescribing information GB

MAT-XU-2202578 (v4.0)
Date of preparation: June 2024

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MAT-XU-2202567 (v3.0) Date of Preparation: June 2024